Literature DB >> 20803209

Treatment of recurrent vulvar Paget disease with imiquimod cream: a case report and review of the literature.

Esra Tonguc1, Tayfun Güngor, Turgut Var, Mustafa Ozat, Izzet Sahin, Levent Sirvan.   

Abstract

INTRODUCTION: Extra-mammary Paget disease is one of the rare neoplastic conditions of the skin. The most common site of involvement is the vulva and presents itself with erythematous plaques. Surgery is the most important treatment option. In the recent years, there are publications of the topical use of imiquimod cream in extra-mammary cutaneous Paget disease. We report the case of a woman with recurrent vulvar Paget disease, who underwent successful treatment with imiquimod cream. We also review the reports of other patients with vulvar Paget disease who were treated with topical imiquimod cream. CASE REPORT: A 65-year-old woman presented to the Oncology Outpatient Clinic with an itchy lesion in her vulva for 2 years. In the gynecologic examination, a hyperkeratotic erythematous lesion was found starting from the right labium to involve clitoris, with a size of 4 × 3 cm. Pathology result was reported as Paget disease. She was operated and wide vulvar excision was performed with a safety margin of 2 cm. Then recurrence two times occurred. Because she refused surgery, imiquimod cream 5% was applied for treatment.
CONCLUSION: Imiquimod cream is an effective and safe therapeutic agent for both primary and recurring vulvar Paget disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803209     DOI: 10.1007/s00404-010-1653-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  20 in total

Review 1.  Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.

Authors:  Giovanni Mantovani; Giulia Gramignano; Valerio Mais; Gian Benedetto Melis; Giuseppina Parodo; Giuseppe Mario Carrucciu
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-05-12       Impact factor: 2.435

2.  Maternal CA-125 levels in pregnancy and the puerperium.

Authors:  M Spitzer; N Kaushal; F Benjamin
Journal:  J Reprod Med       Date:  1998-04       Impact factor: 0.142

3.  Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.

Authors:  A K Sood; M S Shahin; J I Sorosky
Journal:  Gynecol Oncol       Date:  2001-12       Impact factor: 5.482

Review 4.  Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review.

Authors:  Gabriella Ferrandina; Mariagrazia Distefano; Antonia Testa; Rosa De Vincenzo; Giovanni Scambia
Journal:  Gynecol Oncol       Date:  2005-05       Impact factor: 5.482

Review 5.  Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer.

Authors:  Ana M Gonzalez-Angulo; Ronald S Walters; Robert J Carpenter; Merrick I Ross; George H Perkins; Karin Gwyn; Richard L Theriault
Journal:  Clin Breast Cancer       Date:  2004-10       Impact factor: 3.225

Review 6.  Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review.

Authors:  M Modares Gilani; M Karimi Zarchi; N Behtash; F Ghaemmaghami; A S Mousavi; F Behnamfar
Journal:  Int J Gynecol Cancer       Date:  2007-04-12       Impact factor: 3.437

Review 7.  Ovarian cancer in pregnancy: a clinicopathologic analysis of 22 cases and review of the literature.

Authors:  X Y Zhao; H F Huang; L J Lian; J H Lang
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

Review 8.  Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors.

Authors:  Hatem A Azim; Fedro A Peccatori; Nicholas Pavlidis
Journal:  Cancer Treat Rev       Date:  2009-12-16       Impact factor: 12.111

Review 9.  Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review.

Authors:  Olivier Picone; Catherine Lhommé; Michel Tournaire; Patricia Pautier; Sophie Camatte; Marie-Cecile Vacher-Lavenue; Damienne Castaigne; Philippe Morice
Journal:  Gynecol Oncol       Date:  2004-08       Impact factor: 5.482

Review 10.  Use of chemotherapy during human pregnancy.

Authors:  Elyce Cardonick; Audrey Iacobucci
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

View more
  7 in total

1.  Multiple concurrent primary extramammary Paget's disease.

Authors:  M Leelavathi; M N Norazirah; A P Nur Amirah
Journal:  Malays Fam Physician       Date:  2016-04-30

2.  Treatment of vulvar Paget disease with topical imiquimod: a case report and review of the literature.

Authors:  Laurence Feldmeyer; Katrin Kerl; Jivko Kamarashev; Pierre de Viragh; Lars E French
Journal:  J Dermatol Case Rep       Date:  2011-09-21

Review 3.  Effects of imiquimod on vulvar Paget's disease: a systematic review of literature.

Authors:  Hiroko Machida; Aida Moeini; Lynda D Roman; Koji Matsuo
Journal:  Gynecol Oncol       Date:  2015-07-17       Impact factor: 5.482

4.  Clinical treatment of vulvar Paget's disease: a case report.

Authors:  Cristina Anton; Arthur Vicentini da Costa Luiz; Filomena Marino Carvalho; Edmund Chada Baracat; Jesus Paula Carvalho
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease.

Authors:  Soraya Marcos; Angel Montero; Belén Capuz; Javier Martinez-Ollero; Raúl Hernanz; Eva Fernández; Alfredo Polo; Alfredo Ramos
Journal:  Rep Pract Oncol Radiother       Date:  2012-05-03

6.  Interventions for the treatment of Paget's disease of the vulva.

Authors:  Katharine A Edey; Ernest Allan; John B Murdoch; Susan Cooper; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2019-06-05

Review 7.  Axillary Paget disease with a visible satellite: a case report and literature review.

Authors:  Wu-Yang Ji; Bin Luo; Xue-Wei Wang; Ying Xiao; Jin-Yi Tian
Journal:  Diagn Pathol       Date:  2021-08-01       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.